{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:00:31Z","timestamp":1777546831683,"version":"3.51.4"},"publisher-location":"Totowa, NJ","reference-count":32,"publisher":"Humana Press","isbn-type":[{"value":"9781627032681","type":"print"},{"value":"9781627032698","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T00:00:00Z","timestamp":1351555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T00:00:00Z","timestamp":1351555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-1-62703-269-8_9","type":"book-chapter","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T16:23:30Z","timestamp":1364228610000},"page":"149-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies"],"prefix":"10.1007","author":[{"given":"Sebastian","family":"B\u00f6ttcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kneba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,30]]},"reference":[{"key":"9_CR00091","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","volume":"107","author":"C Pott","year":"2006","unstructured":"Pott C, Schrader C, Gesk S et al (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271\u20132278","journal-title":"Blood"},{"key":"9_CR00092","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215\u20133223","journal-title":"Blood"},{"key":"9_CR00093","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004\u20134013","journal-title":"Blood"},{"key":"9_CR00094","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","volume":"91","author":"A Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cabanillas F, McLaughlin P et al (1998) The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955\u20132960","journal-title":"Blood"},{"key":"9_CR00095","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101\u2013106","journal-title":"Blood"},{"key":"9_CR00096","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.V99.3.856","volume":"99","author":"A Rambaldi","year":"2002","unstructured":"Rambaldi A, Lazzari M, Manzoni C et al (2002) Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99:856\u2013862","journal-title":"Blood"},{"key":"9_CR00097","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P Moreton","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971\u20132979","journal-title":"J Clin Oncol"},{"key":"9_CR00098","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood.V98.1.29","volume":"98","author":"AC Rawstron","year":"2001","unstructured":"Rawstron AC, Kennedy B, Evans PA et al (2001) Quantitation of minimal residual disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29\u201335","journal-title":"Blood"},{"key":"9_CR00099","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","volume":"107","author":"C Moreno","year":"2006","unstructured":"Moreno C, Villamor N, Colomer D et al (2006) Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107:4563\u20134569","journal-title":"Blood"},{"key":"9_CR000910","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.2008.16.4459","volume":"27","author":"N Lamanna","year":"2009","unstructured":"Lamanna N, Jurcic JG, Noy A et al (2009) Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 27:491\u2013497","journal-title":"J Clin Oncol"},{"key":"9_CR000911","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2010.89","volume":"24","author":"L Ysebaert","year":"2010","unstructured":"Ysebaert L, Gross E, Kuhlein E et al (2010) Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 24:1310\u20131316","journal-title":"Leukemia"},{"key":"9_CR000912","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/leu.2009.133","volume":"23","author":"JE Castro","year":"2009","unstructured":"Castro JE, James DF, Sandoval-Sus JD et al (2009) Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 23:1779\u20131789","journal-title":"Leukemia"},{"key":"9_CR000913","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00277-009-0742-6","volume":"88","author":"K Maloum","year":"2009","unstructured":"Maloum K, Settegrana C, Chapiro E et al (2009) IGHV gene mutational status and LPL\/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Ann Hematol 88:1215\u20131221","journal-title":"Ann Hematol"},{"key":"9_CR000914","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S Bottcher","year":"2012","unstructured":"Bottcher S, Ritgen M, Fischer K et al (2012) Minimal residual disease quantification is an independent predictor of progression free and overall survival in chronic lymphocytic leukemia. A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30:980\u2013988","journal-title":"J Clin Oncol"},{"key":"9_CR000915","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2141.2004.05120.x","volume":"126","author":"MH Bakkus","year":"2004","unstructured":"Bakkus MH, Bouko Y, Samson D et al (2004) Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 126:665\u2013674","journal-title":"Br J Haematol"},{"key":"9_CR000916","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","volume":"28","author":"M Ladetto","year":"2010","unstructured":"Ladetto M, Pagliano G, Ferrero S et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28:2077\u20132084","journal-title":"J Clin Oncol"},{"key":"9_CR000917","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","volume":"112","author":"B Paiva","year":"2008","unstructured":"Paiva B, Vidriales MB, Cervero J et al (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017\u20134023","journal-title":"Blood"},{"key":"9_CR000918","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","volume":"100","author":"AC Rawstron","year":"2002","unstructured":"Rawstron AC, Davies FE, Dasgupta R et al (2002) Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 100:3095\u20133100","journal-title":"Blood"},{"key":"9_CR000919","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","volume":"99","author":"JF San Miguel","year":"2002","unstructured":"San Miguel JF, Almeida J, Mateo G et al (2002) Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 99:1853\u20131856","journal-title":"Blood"},{"key":"9_CR000920","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","volume":"116","author":"P Dreger","year":"2010","unstructured":"Dreger P, Dohner H, Ritgen M et al (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116:2438\u20132447","journal-title":"Blood"},{"key":"9_CR000921","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/leu.2008.96","volume":"22","author":"M Ritgen","year":"2008","unstructured":"Ritgen M, Bottcher S, Stilgenbauer S et al (2008) Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 22:1377\u20131386","journal-title":"Leukemia"},{"key":"9_CR000922","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/sj.leu.2403478","volume":"18","author":"S Bottcher","year":"2004","unstructured":"Bottcher S, Ritgen M, Pott C et al (2004) Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 18:1637\u20131645","journal-title":"Leukemia"},{"key":"9_CR000923","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3324\/haematol.11267","volume":"93","author":"S Bottcher","year":"2008","unstructured":"Bottcher S, Ritgen M, Buske S et al (2008) Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 93:551\u2013559","journal-title":"Haematologica"},{"key":"9_CR000924","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A et al (2007) Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604\u2013611","journal-title":"Leukemia"},{"key":"9_CR000925","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/leu.2009.140","volume":"23","author":"S Bottcher","year":"2009","unstructured":"Bottcher S, Stilgenbauer S, Busch R et al (2009) Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 23:2007\u20132017","journal-title":"Leukemia"},{"key":"9_CR000926","first-page":"1365","volume":"90","author":"ME Sarasquete","year":"2005","unstructured":"Sarasquete ME, Garcia-Sanz R, Gonzalez D et al (2005) Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90:1365\u20131372","journal-title":"Haematologica"},{"key":"9_CR000927","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956\u2013964","journal-title":"Leukemia"},{"key":"9_CR000928","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron AC, Orfao A, Beksac M et al (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93:431\u2013438","journal-title":"Haematologica"},{"key":"9_CR000929","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/sj.leu.2404416","volume":"20","author":"AC Rawstron","year":"2006","unstructured":"Rawstron AC, de Tute R, Jack AS et al (2006) Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 20:2102\u20132110","journal-title":"Leukemia"},{"key":"9_CR000930","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","volume":"26","author":"G Mateo","year":"2008","unstructured":"Mateo G, Montalban MA, Vidriales MB et al (2008) Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 26:2737\u20132744","journal-title":"J Clin Oncol"},{"issue":"9","key":"9_CR000931","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores J, van der Velden VH et al (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26(9):1986\u20132010","journal-title":"Leukemia"},{"key":"9_CR000932","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.V91.7.2588","volume":"91","author":"C Bomberger","year":"1998","unstructured":"Bomberger C, Singh-Jairam M, Rodey G et al (1998) Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 91:2588\u20132600","journal-title":"Blood"}],"container-title":["Methods in Molecular Biology","Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-62703-269-8_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T13:18:40Z","timestamp":1675948720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-62703-269-8_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,30]]},"ISBN":["9781627032681","9781627032698"],"references-count":32,"URL":"https:\/\/doi.org\/10.1007\/978-1-62703-269-8_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,30]]},"assertion":[{"value":"30 October 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}